{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:19:31Z","timestamp":1773922771736,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T00:00:00Z","timestamp":1515196800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00277-017-3224-2","type":"journal-article","created":{"date-parts":[[2018,1,6]],"date-time":"2018-01-06T03:35:47Z","timestamp":1515209747000},"page":"597-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)"],"prefix":"10.1007","volume":"97","author":[{"given":"Raihane","family":"Ben Lakhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4390-7716","authenticated-orcid":false,"given":"Hela","family":"Ghedira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem","family":"Bellaaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosra","family":"Ben Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Menif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeineb","family":"Manai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Bedoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amel","family":"Lakhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fehmi","family":"M\u2019Sadek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moez","family":"Elloumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abderrahmane","family":"Kh\u00e9lif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neila","family":"Ben Romdhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Adn\u00e8ne","family":"Laatiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Ben Othmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balkis","family":"Meddeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,6]]},"reference":[{"issue":"6","key":"3224_CR1","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/cncr.22498","volume":"109","author":"Z Aziz","year":"2007","unstructured":"Aziz Z, Iqbal J, Akram M, Saeed S (2007) Treatment of chronic myeloid leukemia in the imatinib era perspective from a developing country. Cancer 109(6):1138\u20131145. https:\/\/doi.org\/10.1002\/cncr.22498","journal-title":"Cancer"},{"key":"3224_CR2","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2010.03.033","volume":"34","author":"K Dong-Wook","year":"2010","unstructured":"Dong-Wook K, Shripad DB, Udomsak B et al (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 34:1459\u20131471","journal-title":"Leuk Res"},{"issue":"6","key":"3224_CR3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/cncr.21756","volume":"106","author":"JE Cortes","year":"2006","unstructured":"Cortes JE, Talpaz M, O\u2019Brien S et al (2006) Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106(6):1306\u20131315. https:\/\/doi.org\/10.1002\/cncr.21756","journal-title":"Cancer"},{"issue":"6","key":"3224_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 108(6):1809\u20131820. https:\/\/doi.org\/10.1182\/blood-2006-02-005686","journal-title":"Blood"},{"issue":"35","key":"3224_CR5","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. JCO 27(35):6041\u20136051. https:\/\/doi.org\/10.1200\/JCO.2009.25.0779","journal-title":"JCO"},{"issue":"6","key":"3224_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"issue":"3","key":"3224_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","volume":"22","author":"M Rohrbacher","year":"2009","unstructured":"Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):295\u2013302. https:\/\/doi.org\/10.1016\/j.beha.2009.07.007","journal-title":"Best Pract Res Clin Haematol"},{"key":"3224_CR8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1590\/S1516-84842005000300005","volume":"27","author":"VA Funke","year":"2005","unstructured":"Funke VA, Medeiro CR, Lima DH et al (2005) Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases. Rev Bras Hematol Hemoter 27:159\u2013165","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"4","key":"3224_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3816\/CLK.2008.n.036","volume":"2","author":"A Aguayo","year":"2008","unstructured":"Aguayo A, Garcia-Alvarez E, Cazares-Ordonez Y, Crespo-Solis E, Martinez-Ba\u00f1os D, Guadarrama-Beltran E, Cervera-Ceballos EE, Lopez-Karpovitch X (2008) Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution in Mexico City. Clin Leuk 2(4):261\u2013266. https:\/\/doi.org\/10.3816\/CLK.2008.n.036","journal-title":"Clin Leuk"},{"issue":"11","key":"3224_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"issue":"23","key":"3224_CR11","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408\u20132417. https:\/\/doi.org\/10.1056\/NEJMoa062867","journal-title":"N Engl J Med"},{"issue":"12","key":"3224_CR12","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/cncr.11831","volume":"98","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes J et al (2003) Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98(12):2636\u20132642. https:\/\/doi.org\/10.1002\/cncr.11831","journal-title":"Cancer"},{"key":"3224_CR13","unstructured":"Rodrigues Lemos JA, Quinto Bentes A, Sim\u00f5es Beltr\u00e3o AC et al (2010) Late diagnosis and delayed treatment combined as a cause of suboptimal response to imatinib in chronic myeloid leukemia in developing countries, 116. Blood, Dent Abstr 4750"},{"issue":"3","key":"3224_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686\u2013692. https:\/\/doi.org\/10.1182\/blood-2010-12-319038","journal-title":"Blood"},{"issue":"21","key":"3224_CR15","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1182\/blood.V122.21.5196.5196","volume":"122","author":"J Zelada","year":"2013","unstructured":"Zelada J, Capurro MPA, Rojas B et al (2013) Is EUTOS score predictive of outcome in patients with early chronic phase chronic myeloid leukemia treated with imatinib? Preliminary data from the National Protocol of the Chilean Cooperative Group Panda. Blood 122(21):5196","journal-title":"Blood"},{"key":"3224_CR16","first-page":"25","volume":"2","author":"AA Oyekunle","year":"2012","unstructured":"Oyekunle AA, Osho PO, Aneke JC et al (2012) The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era. J Hematol Malig 2:25\u201332","journal-title":"J Hematol Malig"},{"issue":"5","key":"3224_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","volume":"35","author":"T Tauchi","year":"2011","unstructured":"Tauchi T, Kizakib M, Okamotoc S et al (2011) Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 35(5):585\u2013590. https:\/\/doi.org\/10.1016\/j.leukres.2010.10.027","journal-title":"Leuk Res"},{"issue":"1","key":"3224_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clml.2012.07.009","volume":"13","author":"HM Kantarjian","year":"2013","unstructured":"Kantarjian HM, Larson RA, Cort\u00e9s JE, Deering KL, Mauro MJ (2013) Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 13(1):48\u201354. https:\/\/doi.org\/10.1016\/j.clml.2012.07.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"3224_CR19","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, M\u00fcller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, H\u00e4nel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Sau\u00dfele S (2011) Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12):1634\u20131642. https:\/\/doi.org\/10.1200\/JCO.2010.32.0598","journal-title":"J Clin Oncol"},{"key":"3224_CR20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ejh.12453","volume":"95","author":"S Lapusan","year":"2014","unstructured":"Lapusan S, Yong A, Savani BN et al (2014) Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points. Eur J Haematol 95:103\u2013111","journal-title":"Eur J Haematol"},{"issue":"24","key":"3224_CR21","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintas-Cardama A, Cortes J (2013) Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 121(24):4867\u20134874. https:\/\/doi.org\/10.1182\/blood-2013-03-490128","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3224-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3224-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3224-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T08:23:05Z","timestamp":1603614185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3224-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,6]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["3224"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3224-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,6]]}}}